2023 World Conference on Lung Cancer (Posters)-P1.25. Stereotactic Ablative Body Radiotherapy for Early NSCLC: Changes in Pulmonary Function, Dyspnoea and Quality of Life

P1.25. Stereotactic Ablative Body Radiotherapy for Early NSCLC: Changes in Pulmonary Function, Dyspnoea and Quality of Life - PDF(Abstract)

Back to course

Pdf Summary

This study focused on the use of stereotactic ablative body radiotherapy (SABR) as an alternative to surgery for early-stage non-small cell lung cancer (NSCLC). The researchers aimed to evaluate the impact of SABR on pulmonary function tests (PFT), dyspnea, and quality of life (QoL) in NSCLC patients. <br /><br />A prospective cohort of 119 NSCLC patients treated with SABR was included in the study. PFTs were obtained at baseline and every 6 months up to 60 months. The researchers analyzed potential predictors of PFT decline, including COPD, smoking pack years, age, tumor location, and lung dosimetry. Dyspnea was assessed through clinician-reported and patient-reported outcomes, and QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire.<br /><br />The findings showed a minor decline in FEV1, FVC, and DLCO, with a statistically significant decline in FEV1 at 18 months post-SABR. Smoking pack years was found to be a predictor for the decline in DLCO and FEV1. However, there was no significant decline in observed walking distance or clinician-reported dyspnea.<br /><br />Patient-reported outcomes revealed a statistically significant worsening in dyspnea scores at the 18-month time point, but not earlier. There was no significant change in the global QoL scores at any time points.<br /><br />Overall, this study provides a comprehensive assessment of the impact of SABR on NSCLC patients, demonstrating a small but statistically significant decline in PFTs at 18 months post-treatment. Smoking pack years was associated with a decline in lung function. Dyspnea scores worsened over time, suggesting the progression of lung co-morbid disease, but there was no worsening in global health scores. These findings contribute to a better understanding of the outcomes and effects of SABR in early NSCLC.

Asset Subtitle

Julie Ahn

Meta Tag

Speaker Julie Ahn

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

SABR

NSCLC

PFT

dyspnea

QoL

COPD

smoking pack years

FEV1

FVC

DLCO